

# **ENCOUNTER KEYS**

March-April 2022

Inside this Edition	Page
Notice from the Office of the Inspector General Encounter File Pro- cessing Schedule Age Changes	1
Code Updates	2
Coverage Code	3-5
Follow Up Days	6
Limits & Frequencies	7
Modifiers	7-11
New Codes	12
Provider Types	13
Place of Service	14-16
Procedure Daily Maximum Revenue Code RF129 MUE Occurrence Span	17

# From the Office of the Inspector General

AHCCCS has revised the provider participation agreement and the group biller participation agreement. The new agreements are available for review on the <u>AHCCCS website</u>. Changes to the agreements are generally deemed accepted by providers and group billers 30 days after the date of publishing. More details on this and other terms of the agreement are set forth in the application form.

#### **Encounter File Processing Schedule**

The Encounter File Processing Schedule for April 2022 – June 2022 can be found on the AHCCCS website.

#### **Age Changes**

The Age on the Reference Screen RF223 (ICD-10 Diagnosis Code) has been changed for the following:

- P09. 1 Abnormal finding on neonatal screening for inborn errors of metabolism
- P09. 2 Abnormal findings on neonatal screening for congenital endocrine disease
- P09. 3 Abnormal findings on neonatal screening for congenital hematologic disorders
- P09. 4 Abnormal findings on neonatal screening for cystic fibrosis
- P09. 5 Abnormal findings on neonatal screening for critical congenital heart disease
- P09. 6 Abnormal Findings on Neonatal Screening for neonatal hearing loss codes to:

Minimum Age: 000 Y Year Maximum Age: 999 Y Year



# **Code Updates**

- Effective for March 31, 2022 the ICD-10 code Z28.3 (Under Immunization Status) will have a **coverage code of 04** (Not Covered Service/Code Not Available).
- ◆ The code 99458 (Remote Physiologic Monitoring) has been **end dated** as of December 31, 2021 on RFC25 (Status Code B CPT-HCPCS Codes ).
- Effective for February 11, 2022 the following codes have been added to the Reference Screens.

Code	Description
Q0222	Injection, Bebtelovimab, 175 mg
	Intravenous Injection, Bebtelovimab, Includes Injection and Post Administration Monitor-
M0222	ing
	Intravenous Injection, Bebtelovimab, Includes Injection and Post Administration Monitoring In The Home Or Residence; This Includes A Beneficiary's Home That Has Been Made
M0223	Provider-Based To The Hospital During The Covid-19 Public Health Emergency

• Effective for April 1, 2022 the following CPT/HCPCS codes have been added to the Reference Screen. For Descriptions, Coverage Code, etc. refer to the Reference Screens.

Codes				
0306U	0320U	C9507	K1030	
0307U	0321U	C9781	K1031	
0308U	0322U	C9782	K1032	
0309U	A2011	C9783	K1033	
0310U	A2012	E2102	Q4224	
0311U	A2013	H2038	Q4225	
0312U	A4100	J0219	Q4256	
0313U	A4238	J0491	Q4257	
0314U	A9291	J0879	Q4258	
0315U	A9574	J9071	Q5124	
0316U	C9090	J9273	T2050	
0317U	C9091	J9359	T2051	
0318U	C9092	K1028	V2525	
0319U	C9093	K1029		

# **Coverage Code**

Effective for January 2, 2022 the following now have Coverage Code of 04 (Not Covered Service/Code Not Available).

Code	Description	Code	Description
M1072	Radiation Therapy for Anal Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Compo- nent	M1073	Radiation Therapy for Anal Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component
M1074	Radiation Therapy for Bladder Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Compo- nent	M1075	Radiation Therapy for Bladder Cancer Un- der the Radiation Oncology Model, 90 Day Episode, Technical Compoent
M1076	Radiation Therapy for Bone Metasta- ses Under the Radiation Oncology Model, 90 Day Episode, Professional Component	M1077	Radiation Therapy for Bone Metastases Under the Radiation Oncology Model, 90 Day Episode, Professional Component
M1078	Radiation Therapy for Brain Metasta- ses Under the Radiation Oncology Model, 90 Day Episode, Professional Component	M1089	Radiation Therapy for Head and Neck Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Compo- nent
M1094	Radiation Therapy for Lung Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Compo- nent	M1095	Radiation Therapy for Lung Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component
M1096	Radiation Therapy for Lymphoma Un- der the Radiation Oncology Model, 90 Day Episode, Professional Component	M1097	Radiation Therapy for Lymphoma Under the Radiation Oncology Model, 90 Day Episode, Technical Component
M1098	Radiation Therapy for Pancreatic Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Component	M1099	Radiation Therapy for Pancreatic Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component
M1100	Radiation Therapy for Prostate Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Compo- nent	M1101	Radiation Therapy for Prostate Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component
M1102	Radiation Therapy for Upper Gi Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Component	M1103	Radiation Therapy for Upper Gi Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component
M1104	Radiation Therapy for Uterine Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Compo- nent	M1105	Radiation Therapy for Uterine Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component

• Effective for January 1, 2022 the following now have Coverage Code of 10 (Non Pay Category 2 Codes).

M1079	Radiation Therapy for Brain Metastases Under the Radiation Oncology Model, 90 Day Episode, Technical Component	M1080	Radiation Therapy for Breast Cancer Under the Radiation Oncology Model, 90 Day Epi- sode, Professional Component
M1081	Radiation Therapy for Breast Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component	M1082	Radiation Therapy for Cervical Cancer Under the Radiation Oncology Model, 9 Day Episode, Professional Compo- nent
M1083	Radiation Therapy for Cervical Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component	M1084	Radiation Therapy for CNS Tumors Under the Radiation Oncology Model, 90 Day Episode, Professional Component
M1085	Radiation Therapy for CNS Tumors Under the Radiation Oncology Model, 90 Day Episode, Technical Component	M1086	Radiation Therapy for Colorectal Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Component
M1087	Radiation Therapy for Colorectal Cancer Under the Radiation Oncology Model, 90 Day Episode, Technical Component	M1088	Radiation Therapy for Head and Neck Cancer Under the Radiation Oncology Model, 90 Day Episode, Professional Component

• Effective for dates listed, the following codes now have had their coverage code changed.

			Effective
Code	Description	Coverage Code	Date
81420	Test For Detecting Genes Associated with Fetal Disease, Aneuploidy Genomic Sequence Analy-	01 - Covered Service/Code Available	3/1/2021
81507	DNA Analysis Using Maternal Plasma	01 - Covered Service/Code Available	3/1/2021
91305	Coronavirus Vaccine 6	03 - Covered Service/Use Other Code	1/3/2022
91307	Coronavirus Vaccine 8	03 - Covered Service/Use Other Code	10/29/2021
0051A	Administration Of Coronavirus Vaccine 6, Dose 1	01 - Covered Service/Code Available	1/3/2022
0052A	Administration Of Coronavirus Vaccine 6, Dose 2	01 - Covered Service/Code Available	1/3/2022
0053A	Administration Of Coronavirus Vaccine 6, Booster	01 - Covered Service/Code Available	1/3/2022
0054A	Administration Of Coronavirus Vaccine 6, Reserved	01 - Covered Service/Code Available	01/03/2022
0071A	Administration Of Coronavirus Vaccine 8, Dose 1	01 - Covered Service/Code Available	10/29/2021
0072A	Administration Of Coronavirus Vaccine 8, Dose 2	01 - Covered Service/Code Available	10/29/2021
0073A	Administration Of Coronavirus Vaccine 8, Booster	01 - Covered Service/Code Available	3/1/2022

• Effective for dates listed, the following codes now have had their coverage code changed.

Code	Description	Coverage Code	Effective Date
	·		
0053A	Administration Of Coronavirus Vaccine 6, Booster	01 Covered Service/Code Available	01/03/2022
	Administration Of Coronavirus Vaccine 6, Re-		
0054A	served	01 Covered Service/Code Available	01/03/2022
0071A	Administration Of Coronavirus Vaccine 8, Dose 1	01 Covered Service/Code Available	10/29/2021
0072A	Administration Of Coronavirus Vaccine 8, Dose 2	01 Covered Service/Code Available	10/29/2021
0073A	Administration Of Coronavirus Vaccine 8, Booster	01 Covered Service/Code Available	03/01/2022
91305	Coronavirus Vaccine 6	03 Covered Service/Use Other Code	01/03/2022
91307	Coronavirus Vaccine 8	03 Covered Service/Use Other Code	10/29/2021

# **Follow Up Days**

The Follow Up Days on the Reference Screens have been changed for the following codes.

Code	Description	Days
0672T	Radiofrequency Remodeling of Tissues Surrounding Female	000 days
0673T	Laser Destruction of Benign Growth of Thyroid Using Im	000 days
0674T	Insertion Of Permanent Implantable Synchronized Diaphragm	000 days
0675T	Insertion Of First Lead of Permanent Implantable Synch	000 days
0676T	Insertion Of Additional Lead of Permanent Implantable	000 days
0677T	Repositioning Of First Lead of Permanent Implantable	000 days
0678T	Repositioning Of Additional Lead of Permanent Implantable	000 days
0679T	Removal Of Permanent Implantable Synchronized Diaphragm	000 days
0680T	Insertion Or Replacement of Pulse Generator	000 days
0681T	Relocation Of Pulse Generator Only of Permanent Implantable	000 days
0682T	Removal Of Pulse Generator Only of Permanent Implantable	000 days
0683T	In-Person Programming Device Evaluation of Permanent I	000 Days
0684T	In-Person Programming Device Evaluation and Programming	000 Days
0685T	In-Person Interrogation Device Evaluation of Permanent	000 Days
0686T	Acoustic Energy Destruction of Malignant Liver Tissue	000 Days
0689T	Quantitative Ultrasound Tissue Characterization	000 Days
0690T	Quantitative Ultrasound Tissue Characterization With	000 Days
33268	Exclusion Of Appendage of Left Upper Chamber of Heart	000 Days
33370	Placement And Subsequent Removal of Device to Protect	000 Days
33509	Harvest Of Artery from Arm for Heart Bypass Graft Using an Endoscope	000 Days
33894	Repair Of Aorta by Insertion of Stent Across Major Sid	000 Days
33895	Repair Of Aorta by Insertion of Stent Not Crossing Maj	000 Days
33897	Balloon Dilation of Native or Recurrent Narrowing of Heart	000 Days
53451	Insertion Of Adjustable Balloon Continence Device On B	010 Days
53452	Insertion Of Adjustable Balloon Continence Device On O	010 Days
61736	Laser Interstitial Thermal Therapy (LITT) Of Single	000 Days
61737	Laser Interstitial Thermal Therapy (LITT) Of Multiple	000 Days
63052	Partial Removal of Bone of Single Segment of Spine	000 Days
64582	Insertion Of Hypoglossal Nerve Neurostimulator Electro	090 Days
64583	Revision Or Replacement of Hypoglossal Nerve Neurostimulator Electrode	090 Days
64584	Removal Of Hypoglossal Nerve Neurostimulator Electrode	090 Days
64629	Heat Destruction of Intraosseous Basivertebral Nerve	000 days

# **Limits and Frequencies**

The following codes have had all limits and frequencies removed from the Reference Screens.

CODES				
V2020	V2110	V2203	V2215	
V2025	V2111	V2204	V2218	
V2100	V2112	V2205	V2219	
V2101	V2113	V2206	V2220	
V2102	V2114	V2207	V2221	
V2103	V2115	V2208	V2299	
V2104	V2118	V2209	V2300	
V2105	V2121	V2210	V2301	
V2106	V2199	V2211	V2302	
V2107	V2200	V2212	V2303	
V2108	V2201	V2213	V2304	
V2109	V2202	V2214	V2305	

# **Modifiers**

• Effective for January 1, 2021 the modifiers JA (Administered Intravenously) and JB (Administered Subcutaneously) have been added to the Reference Screens.

Code	Description	Code	Description
J0517	Injection, Benralizumab, 1 mg	J2793	Injection, Rilonacept, 1 mg
J0638	Injection, Canakinumab, 1 mg	J3245	Injection, Tildrakizumab, 1 mg
J0717	Injection, Certolizumab Pegol, 1 mg	Q5101	Injection, Filgrastim-SNDZ, Biosimilar, (Zarxio), 1 Microgram
J0896	Injection, Luspatercept-Aamt, 0.25 mg	Q5108	Injection, Pegfilgrastim-Jmdb, Biosimilar, (Fulphila), 0.5 mg
J1442	Injection, Filgrastim (G-CSF), Excludes Biosimilars,	Q5110	Injection, Filgrastim-Aafi, Biosimilar, (Nivestym), 1 Microgram
J2182	Injection, Mepolizumab, 1 mg	Q5111	Injection, Pegfilgrastim-Cbqv, Biosimilar, (Udenyca), 0.5 mg

			Effective
			Begin
Code	Description	Modifier	Date
		78 - Return To O.R. For Related Pro-	
20702	Insertion Of Drug-Delivery Device In Bone	cedure Post-OP	9/1/2021
	Repositioning Of Tube Open Procedure for Ecmo		
	External Blood Circulation In Heart and Lungs	63 - Neonates/Infants Up to the 4-KG	
33959	Using A Pump (5 Years or Younger)	Cut Off	10/1/2021
		82 - Assist Surg/Qual Resident Surg	
47379	Unlisted Laparoscopic Procedure, Liver	Not Avail	1/1/2020
	Other Procedure on Bile Duct Using an Endo-		
47579	scope	81 - Minimum Assistant Sur	6/1/2021
74248	Follow-Through X-Ray of Small Intestines	Q6 - Fee/Time Comp Subst MD or PT	2/1/2021
	Complex Radiation Therapy Planning for Delivery		
77318	of Inte	PN - Non-Excepted Service Pro	7/1/2021
90791	Psychiatric Diagnostic Evaluation	FQ - The Service Was Furnished	1/1/2022
	Individual Psychotherapy, Interactive, Using Play		
90823	Equipment	FQ - The Service Was Furnished	1/1/2022
00000	De destina a 2014 de la	50. The Section West 5 without	4 /4 /2022
90832	Psychotherapy, 30 Minutes	FQ - The Service Was Furnished	1/1/2022
00027	Doughothoropy 1 Hour	TO The Comice Was Furnished	1 /1 /2022
90837	Psychotherapy, 1 Hour	FQ - The Service Was Furnished	1/1/2022
	Injection For Imaging of Coronary Blood Vessel		
93563	During Evaluation of Congenital Abnormalities with Review By Radiologist	63 - Neonates/Infants Up to the 4-KG Cut Off	4/1/2021
93303	Qualified nonphysician health care professional	Cut On	4/1/2021
	online digital evaluation and management ser-		
	vice, for an established patient, for up to 7 days,		
	cumulative time during the 7 days; 11-20	CS – CS Costshare SPEC COVID-19	
98971	minutes	Test Order/A	1/1/2021
	Qualified nonphysician health care professional		
	online digital evaluation and management ser-		
	vice, for an established patient, for up to 7 days,		
000==	cumulative time during the 7 days; 21 or more	CS – CS Costshare SPEC COVID-19	4/4/225
98972	minutes	Test Order/A	1/1/2021
	Follow Un Innational Hagnital Critical Care of the		
99472	Follow-Up Inpatient Hospital Critical Care of Infant Or Young Child Per Day (29 Days To 2 Years)	24 - Unrelated Eval & Mgmt	1/1/2021
33412	Payment for a Telehealth Distant Site Service Fur-	27 - Officiated Eval & Mighit	1/1/2021
G2025	nished	95 - Synchronous Telemedicine	3/18/2020
02023	monea	33 Synthionous referriculation	3/ 10/ 2020

• Effective for dates of service listed the following modifiers have been added or end dated in the system

			Effective	
Code	Description	Modifier	Begin Date	End Date
		78 - Return To O.R. For Related		
20702	Insertion Of Drug-Delivery Device In Bone	Procedure Post-OP	9/1/2021	
33959	Repositioning Of Tube Open Procedure for Ecmo External Blood Circulation In Heart and Lungs Using A Pump (5 Years or Younger)	63 - Neonates/Infants Up to the 4- KG Cut Off	10/1/2021	
	and the second s	82 - Assist Surg/Qual Resident Surg		
47379	Unlisted Laparoscopic Procedure, Liver	Not Avail	1/1/2020	
74248	Follow-Through X-Ray of Small Intestines	Q6 - Fee/Time Comp Subst MD or PT	2/1/2021	
98971	Qualified nonphysician health care professional online digital evaluation and management service,	CS – CS Costshare SPEC COVID-19 Test Order/A	1/1/2021	
98972	Qualified nonphysician health care professional online digital evaluation and management service, f	CS – CS Costshare SPEC COVID-19 Test Order/A	1/1/2021	
G2025	Payment for a Telehealth Distant Site Service Furnished	95 - Synchronous Telemedicine	3/18/2020	
G2250	Remote assessment of recorded video and/or images submitted by an established patient (e.g., store and forward), including interpretation with follow-up with the patient within 24 business hours, not originating from a related service provided within the previous 7 days nor leading to a service or procedure within the next 24 hours or soonest available appointment	CS – CS Costshare SPEC COVID-19 Test Order/A	1/1/2021	
G2251	Brief communication technology-based service, e.g., virtual check-in, by a qualified health care professional who cannot report evaluation and management services,	CS – CS Costshare SPEC COVID-19 Test Order/A	1/1/2021	
G2252	Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional	CS – CS Costshare SPEC COVID-19 Test Order/A	1/1/2021	
T1015	Clinic Visit/Encounter, All-Inclusive	95 - Synchronous Telemedicine	1/27/2020	6/30/2020
T2007	Transportation Waiting Time, Air Ambulance and Non-Emergency Vehicle, One-Half (1/2) Hour Increments	TU - Special Payment Rate,	2/22/2021	

		No. 115	Effective
Code	Description	Modifier	Begin Date
	Remote assessment of recorded video and/or		
	images submitted by an established patient		
	(e.g., store and forward), including interpreta-		
	tion with follow-up with the patient within 24 business hours, not originating from a related		
	service provided within the previous 7 days nor	CS – CS Costshare SPEC COVID-19 Test	
G2250	leading to a service or procedure within the next 24 hours or soonest available appointment	Order/A	1/1/2021
G2230		Order/A	1/1/2021
	Brief communication technology-based service, e.g., virtual check-in, by a qualified health care		
	professional who cannot report evaluation and		
	management services, provided to an estab-		
	lished patient, not originating from a related		
	service provided within the previous 7 days nor		
	leading to a service or procedure within the		
	next 24 hours or soonest available appoint-	CS – CS Costshare SPEC COVID-19 Test	
G2251	ment: 5-10 minutes of clinical discussion	Order/A	1/1/2021
	Brief communication technology-based service,	,	, ,
	e.g., virtual check-in, by a physician or other		
	qualified health care professional who can re-		
	port evaluation and management services, pro-		
	vided to an established patient, not originating		
	from a related E/M service provided within the		
	previous 7 days nor leading to an e/m service		
	or procedure within the next 24 hours or soon-		
	est available appointment: 11-20 minutes of	CS – CS Costshare SPEC COVID-19 Test	
G2252	medical discussion	Order/A	1/1/2021
	Transportation Waiting Time, Air Ambulance		
	and Non-Emergency Vehicle, One-Half (1/2)		
T2007	Hour Increments	TU - Special Payment Rate,	2/22/2021

<sup>•</sup> Effective for June 30, 2020 the modifier 95 (Synchronous Telemedicine) has been end dated for the HCPCS code T1015 (Clinic Visit/Encounter, All-Inclusive).

• Effective for January 1, 2022 the following modifiers have been added to the Reference Screens.

Code	Description	Modifiers
S5125	Attendant Care Services; Per 15 Minutes	CG
S5130	Homemaker Service, Nos; Per 15 Minutes	CG, UN, UP
S5140	Foster Care, Adult; Per Diem	CG
S5151	Unskilled Respite Care, Not Hospice; Per Diem	CG
T1021	Home Health Aide or Certified Nurse Assistant, Per Visit	CG, UN, UP
T2016	Habilitation, Residential, Waiver; Per Diem	CG, HI, HQ, UN, UP, UQ, UR, US
T2017	Habilitation, Residential, Waiver; 15 Minutes	CG, HI, HN
	Habilitation, Supported Employment, Waiver; Per 15	
T2019	Minutes	HI, HQ, KX, UN, UP, UQ, UR, US
T2021	Day Habilitation, Waiver; Per 15 Minutes	CG, KX, UG, UN,UP, UR, US,

• Effective for June 30, 2020 the modifier 95 (Synchronous Telemedicine) has been end dated for the HCPCS code T1015 (Clinic Visit/Encounter, All-Inclusive).

# New Codes

The following codes have been added to the Reference Screens.

Codo	Description	Effective
Code	Description	Begin Date
91308	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	2/1/2022
31000		
0073A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: third dose	1/3/2022
0081A	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	2/1/2022
000271		-/ -/ -0
	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, dilu-	2/4/2022
0082A	ent reconstituted, tris-sucrose formulation; second dose	2/1/2022
G1028	Take-home supply of nasal naloxone; 2-pack of 8mg per 0.1 ml nasal spray (provision of the services by a Medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure	1/1/2022
J0248	Injection, Remdesivir, 1 mg	12/31/2021
M0220	Injection Tixagevimab and Cilgavimab	12/8/2021
M0221	Tixagevimab and Cilgavimab injection hm	12/8/2021
Q0220	Tixagevimab and Cilgavimab 300 mg	12/8/2021
XW013V7	Introduction of COVID-19 vaccine dose 3 into subcutaneous tissue, percutaneous approach, new technology group 7	4/1/2022
XW013W7	Introduction of COVID-19 vaccine booster into subcutaneous tissue, percutaneous approach, new technology group 7	4/1/2022
XW023V7	Introduction of COVID-19 vaccine dose 3 into muscle, percutaneous approach,	4/1/2022
XW023W7	Introduction of COVID-19 vaccine booster into muscle, percutaneous approach, new technology group 7	4/1/2022
XW0DXR7	Introduction of fostamatinib into mouth and pharynx, external approach, new	4/1/2022
XW0G7R7	Introduction of fostamatinib into upper GI, via natural or artificial opening, new	4/1/2022
XW0H7R7	Introduction of fostamatinib into lower GI, via natural or artificial opening, new technology group 7	4/1/2022
Z28.310	Unvaccinated for COVID-19	4/1/2022
Z28.311	Partially vaccinated for COVID-19	4/1/2022
Z28.39	Other under-immunized status	4/1/2022

### **Provider Type**

- Effective January 1, 2022 provider types 18 (Physician's Assistant) and 19 (Registered Nurse Practitioner) and the Assistant Surgeon modifier (AS) updates were made for applicable codes when AS is allowed for payment.
- ♦ Effective for dates listed the following codes have been added to the Provider Types listed.

Code	Description	Provider Type	Effective Begin Date
87905	Infectious Agent Enzymatic Activity to Detect Organism	19 - Registered Nurse Practitioner	3/1/2021
90697	Diphtheria, Tetanus, Acellular Pertussis, Polio, Haemophilus Influenzae Type B, And Hepatitis B Vaccine	C2 – Federally Qualified Health Center (FQHC)	1/1/2021
90697	Diphtheria, Tetanus, Acellular Pertussis, Polio, Haemophilus Influenzae Type B, And Hepatitis B Vaccine	C5 - 638 FQHC	1/1/2021
90697	Diphtheria, Tetanus, Acellular Pertussis, Polio, Haemophilus Influenzae Type B, And Hepatitis B Vaccine	05 - Clinic	1/1/2021
92060	Exam To Measure Eye Deviation and Range of Motion	IC – Integrated Clinics	10/1/2021

• The following codes have been added to the provider types listed.

Code	Description	Provider type	Begin Date
	Treatment Of Speech, Language, Voice, Communication,	13 - Occupational Ther-	
92508	And/or Hearing Processing Disorder in A Group Setting	apist	01/01/2022

- Effective for dates of service January 1, 2022 the CPT codes below have been added to the provider types C2 (Federally Qualified Health Center (FQHC), C5 (638 FQHC), and IC (Integrated Clinics):
  - 95249 Continuous Monitoring of Blood Sugar Level in Tissue Fluid Using Sensor Under Skin
  - 95250 Continuous Monitoring of Blood Sugar Level in Tissue Fluid Using Sensor Under Skin With Provider Supplied Equipment
  - 95251 Continuous Monitoring of Blood Sugar Level in Tissue Fluid Using Sensor Under Skin with Interpretation and Report

# **Place of Service**

- ♦ Effective for January 28, 2022 the POS 02 (Telehealth Provided Other Than in Patient) has been **end dated** for the HCPCS code T1016 (Case Management, Each 15 Minutes).
- Effective for the dates of service listed the following POS have been **added** to the Reference Screen.

Code	Description	Place of Service	Effective Begin Date
01938	Anesthesia For Injection, drainage or aspiration procedures on spine or spinal cord of lower back accessed through skin using imaging guidance	11 - Office	1/1/2022
01939	Anesthesia For Nerve Destruction Procedures on spine or spinal cord of neck or upper back accessed through skin using imaging guidance	11 - Office	1/1/2022
01940	Anesthesia For Nerve Destruction Procedures on Spine or Spinal Cord of lower back accessed through skin using imaging guidance	11 - Office	1/1/2022
20983	Freezing Of Growth of Bone and Adjacent Soft Tissue	11 - Office	8/1/2021
43194	Removal Of Foreign Bodies from Esophagus Using A Rigid Endoscope	23 - Emergency Room - Hospital	11/1/2021
49440	Insertion Of Stomach Tube Using Fluoroscopic Guidance	11 - Office	8/1/2021
49446	Conversion Of Stomach Tube to Stomach-To-Small Bowel Tube	11 - Office	8/1/2021
49450	Replacement Of Stomach or Large Bowel Tube Using Fluoroscopic Guidance with Contrast	11 - Office	8/1/2021
49452	Replacement Of Stomach-To-Small Bowel Tube Using Fluoroscopic Guidance with Contrast	11 - Office	8/1/2021
69200	Removal Of Foreign Body In Ear Canal	15 - Mobile Unit	10/1/2021
77047	MRI Scan of Both Breasts Without Contrast	11 – Office	5/1/2021
91300	Severe Acute Respiratory Syndrome Coronavirus 2 (Covid- 19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 30 Mcg/0.3ml Dosage, Diluent Reconstituted, For Intra- muscular Use	20 - Urgent Care Facility	11/10/2020
91301	Severe Acute Respiratory Syndrome Coronavirus 2 (Covid- 19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 100 Mcg/0.5ml Dosage, For Intramuscular Use	20 - Urgent Care Facility	11/10/2020
91302	Severe Acute Respiratory Syndrome Coronavirus 2 (Covid- 19) Vaccine, DNA, Spike Protein, Chimpanzee Adenovirus Oxford 1 (Chadox1) Vector, Preservative Free, 5x1010 Vi- ral Particles/0.5ml Dosage, For Intramuscular Use	20 - Urgent Care Facility	12/21/2020

			Effective
Code	Description	Place of Service	Begin Date
	Severe Acute Respiratory Syndrome Corona-		
	virus 2 (Covid-19) Vaccine, DNA, Spike Protein, Adenovirus Type 26 (Ad26) Vector, Pre-		
	servative Free, 5x1010 Viral Particles/0.5ml		
91303	Dosage, For Intramuscular Use	20 - Urgent Care Facility	1/19/2021
31303		·	1/15/2021
93596	Insertion Of Catheter into Right and Left Sides of Heart	Outpatient Hospital	1/1/2022
33330		· ·	1/1/2022
93596	Insertion Of Catheter into Right and Left Sides of Heart		1 /1 /2022
95590		22 - Outpatient Hospital	1/1/2022
00000	Telephone Medical Discussion Provided by	02 - Telehealth Provided	2/20/2022
98966	Nonphysician Professional, 5-10 Minutes	Other Than in Patient	2/28/2022
	Telephone Medical Discussion Provided by	02 - Telehealth Provided	
98967	Nonphysician Professional, 10-20 Minutes	Other Than in Patient	2/28/2022
	Telephone Medical Discussion Provided by	02 - Telehealth Provided	
98968	Nonphysician Professional, 21-30 Minutes	Other Than in Patient	2/28/2022
	Physician Direction of Emergency Advanced	02 - Telehealth Provided	
99288	Life Support Paramedic Services	Other Than in Patient	2/28/2022
	Initial nursing facility visit, typically 45		
99306	minutes per day	21 - Inpatient Hospital	7/1/2020
	Telephone Medical Discussion with Physician,	02 - Telehealth Provided	
99441	5-10 Minutes	Other Than in Patient	2/28/2022
	Telephone Medical Discussion with Physician,	02 - Telehealth Provided	
99442	11-20 Minutes	Other Than in Patient	2/28/2022
	Telephone Medical Discussion with Physician,	02 - Telehealth Provided	
99443	21-30 Minutes	Other Than in Patient	2/28/2022
	Intramuscular Administration of Single Severe		
	Acute Respiratory Syndrome Coronavirus 2		
	(Covid-19) Vaccine, MRNA-LNP, Spike Protein,		
	Preservative Free, 30 Mcg/0.3ml Dosage, Dil-		
0001A	uent Reconstituted; First Dose	20 - Urgent Care Facility	11/10/2020
	Intramuscular Administration of Single Severe		
	Acute Respiratory Syndrome Coronavirus 2		
	(Covid-19) Vaccine, MRNA-LNP, Spike Protein,		
00024	Preservative Free, 30 Mcg/0.3ml Dosage, Dil-	20 Hamout Court Facility	11/10/2020
0002A	uent Reconstituted; Second Dose	20 - Urgent Care Facility	11/10/2020
	Intramuscular Administration of Single Severe		
	Acute Respiratory Syndrome Coronavirus 2		
	(Covid-19) Vaccine, MRNA-LNP, Spike Protein, Preservative Free, 100 Mcg/0.5ml Dosage;		
0011A	First Dose	20 - Urgent Care Facility	11/10/2020
J J T T 1	J	1-2 Significant racinty	,,,

Code	Description	Place of Service	Effective Begin Date
	Intramuscular Administration of Single Severe		
	Acute Respiratory Syndrome Coronavirus 2		
	(Covid-19) Vaccine, MRNA-LNP, Spike Protein,		
	Preservative Free, 100 Mcg/0.5ml Dosage;		
0012A	Second Dose	20 - Urgent Care Facility	11/10/2020
	Intramuscular Administration of Single Severe		
	Acute Respiratory Syndrome Coronavirus 2		
	(Covid-19) Vaccine, DNA, Spike Protein, Chim-		
	panzee Adenovirus Oxford 1 (Chadox1) Vec-		
00244	tor, Preservative Free, 5x1010 Viral Parti-	20 Harrist Court Famility	12/21/2020
0021A	_	20 - Urgent Care Facility	12/21/2020
	Intramuscular Administration of Single Severe		
	Acute Respiratory Syndrome Coronavirus 2 (Covid-19) Vaccine, DNA, Spike Protein, Chim-		
	panzee Adenovirus Oxford 1 (Chadox1) Vec-		
	tor, Preservative Free, 5x1010 Viral Parti-		
0022A		20 - Urgent Care Facility	12/21/2020
002271		20 Orgente out e raemey	12/21/2020
	Intramuscular Administration of Single Severe Acute Respiratory Syndrome Coronavirus 2		
0031A	(Covid-19) Vaccine,	20 - Urgent Care Facility	1/19/2021
0031A		05 - Indian Health Ser-	1/13/2021
0673T	Laser Destruction of Benign Growth of Thy- roid Using Imaging Guidance		1/1/2022
00731			1/1/2022
0673T	,	06 - Indian Health Ser- vice Provider-Bas	1/1/2022
00731	3 3 3		1/1/2022
0673T	,	07 Tribal 638 Free- Standing Facility	1/1/2022
00731	Laser Destruction of Benign Growth of Thy-	Standing racinty	1/1/2022
0673T		11 - Office	1/1/2022
00731	Laser Destruction of Benign Growth of Thy-	19 - Off Campus-	1/1/2022
0673T	roid Using Imaging Guidance	Outpatient Hospital	1/1/2022
00731	Laser Destruction of Benign Growth of Thy-	outputient Hospital	1, 1, 2022
0673T	roid Using Imaging Guidance	21 - Inpatient Hospital	1/1/2022
	Laser Destruction of Benign Growth of Thy-		
0673T	roid Using Imaging Guidance	22 - Outpatient Hospital	1/1/2022
	Laser Destruction of Benign Growth of Thy-	24 - Ambulatory Surgical	
0673T	roid Using Imaging Guidance		1/1/2022
	Behavioral Health Prevention Education Ser-	02 - Telehealth Provided	
H0025	vice		2/28/2022
		02 - Telehealth Provided	
H0038	Self-Help/Peer Services, Per 15 Minutes	Other Than in Patient	2/28/2022
	Skills Training and Development, Per 15	02 - Telehealth Provided	
H2014	Minutes	Other Than in Patient	2/28/2022
	Ongoing Support to Maintain Employment,	02 - Telehealth Provided	
H2025	Per 15 Minutes	Other Than in Patient	2/28/2022
	Injection, Pegfilgrastim, Excludes Biosimilar,		
J2506	0.5 mg	72 – Rural Health Clinic	1/1/2022
		02 - Telehealth Provided	
S5110	Home Care Training, Family; Per 15 Minutes	Other Than in Patient	2/28/2022

### **Procedure Daily Maximum**

The Procedure Daily Maximum has been changed to the following.

		Procedure
		Daily Maxi-
Code	Description	mum
	Ambulance (ALS or BLS) Oxygen and Oxygen Supplies,	
A0422	Life Sustaining Situation	1
J2350	Injection, Ocrelizumab, 1 mg	600

### **Revenue Code**

Effective for July 1, 2022 the revenue code 0161 (Hospital At Home, R) has been added to the reference screen RF721 (Revenue Codes).

# **RF129 MUE Units of Service**

Effective for the dates of service listed on the Reference Screen RF129 the CPT code 36227 has been added. For further information refer to the appropriate screen.

### **Occurrence Span**

The Occurrence Span 82 (Hospital at Home Care Dates) has been added to the reference screen RF746 with an effective date of January 27, 2022.

